A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Connecticut stands out as a prime location for a wide variety of clinical trials, largely thanks to its robust healthcare system and renowned medical research institutions. Leading centers like Yale School of Medicine, UConn Health, and Jackson Laboratory for Genomic Medicine are at the forefront of groundbreaking studies in the state.
Combining a strong focus on innovation and precision medicine makes Connecticut an ideal destination for participants seeking advanced medical treatments and the opportunity to contribute to cutting-edge research.
Why choose Connecticut for clinical trials?
With a diverse and highly educated population, Connecticut offers distinct advantages for those participating in clinical trials, including the opportunity to enhance the reliability and depth of research findings. The vibrant population here makes clinical studies in Connecticut more comprehensive and representative.
By choosing to participate in a clinical trial in Connecticut, individuals contribute to groundbreaking medical research while benefiting from a well-established and supportive clinical research infrastructure, ultimately advancing healthcare for all.
Common conditions studied in Connecticut
Connecticut is a hub for cutting-edge medical research, with clinical trials across a diverse array of conditions. Several institutions contribute significantly to advancements in medicine, reflecting the state’s leadership in both academic research and biotech innovation.
Rare genetic conditions
Connecticut is a leader in studying rare genetic diseases, with local biotech companies and academic institutions collaborating to research conditions such as cystic fibrosis, Duchenne muscular dystrophy, and other hereditary disorders.
Gene therapy and CRISPR-based gene editing are at the forefront of trials, offering promising solutions that could correct genetic mutations at their source. The state’s focus on personalized medicine in this area positions it as a vital contributor in developing therapies that are patient-specific, with the potential for lifelong disease management or cures.
Cardiovascular diseases
Heart disease remains a leading cause of death in the U.S., and Connecticut plays a critical role in studying innovative solutions for cardiovascular diseases. Institutions like the UConn Health Center and Hartford HealthCare Heart & Vascular Institute lead clinical trials on heart failure, hypertension, coronary artery disease, and atrial fibrillation.
These trials explore advancements in minimally invasive surgeries, novel medications, and medical devices, such as next-generation pacemakers, designed to improve outcomes and quality of life for patients with chronic heart conditions.
Cancer
Connecticut is home to prominent cancer research institutions, such as the Yale Cancer Center, which conducts pioneering clinical trials for various types of cancer, including breast cancer, lung cancer, melanoma, and hematological malignancies like leukemia and lymphoma.
The focus for researchers in Connecticut is not only on traditional chemotherapy but also on immunotherapy, targeted therapies, and personalized medicine approaches. This research aims to provide treatments tailored to individual patients' genetic profiles, offering more effective and less invasive options.
Neurological Disorders
Connecticut's focus on neurological diseases like Alzheimer's, Parkinson’s disease, multiple sclerosis (MS), and epilepsy puts it at the forefront of efforts to tackle these complex conditions. Research centers such as Yale School of Medicine run clinical trials aimed at finding new treatments that can slow disease progression or improve early detection through advanced imaging and biomarkers.
Cognitive therapies, neurostimulation techniques, and new pharmacological agents are being tested to manage symptoms and extend patient functionality.
Local regulations and guidelines
In Connecticut, clinical trials are regulated by both federal and state guidelines to ensure the safety and ethical treatment of participants. Federal oversight is provided primarily by the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP), ensuring that all clinical trials comply with national standards for informed consent, ethical treatment, and patient safety.
Trials must also be reviewed and approved by an Institutional Review Board (IRB), which evaluates the study's protocol to ensure that it meets ethical guidelines, protects participants, and balances risks and benefits.
Connecticut-specific regulations may include additional oversight from state health departments, particularly when it comes to the use of investigational drugs or devices. Researchers conducting trials must follow the Connecticut General Statutes that regulate healthcare practices and patient rights, ensuring compliance with local laws governing clinical research.
Benefits of participating in clinical trials
Taking part in a clinical trial provides the unique opportunity to access new and innovative treatments before they are approved and widely available. This can be especially valuable for those with conditions that have not responded to standard therapies. Participants can benefit from expert medical care, with dedicated healthcare professionals offering close monitoring and individualized attention throughout the trial process.
Moreover, participating in clinical trials plays a vital role in advancing medical science, often leading to major breakthroughs in treatments and therapies. By enrolling, individuals not only gain early access to cutting-edge care but also help shape the future of healthcare, contributing to better outcomes for future patients.
Interested in participating in clinical trials but worried about how long they might take? Check out our comprehensive guide for all the information you need to make an informed decision.
How to enroll in a clinical trial in Connecticut
Enrolling in a clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify your trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select your preferred location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore study details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the health profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.